INTRODUCTION
RAS family GTPases represent critical cell signaling nodes involved in many aspects of normal development and function including regulation of proliferation, development, cell survival, and cell motility 1, 2 . However, mutations in one of the three RAS genes (H-, K-or N-RAS) are present in nearly 30% of human tumors underscoring their importance in oncogenic transformation. Indeed, some tumors such as pancreatic adenocarcinomas have an incidence of K-RAS mutations approaching nearly 90%. Furthermore, tumors lacking specific RAS mutation nevertheless frequently employ RAS activity due to mutations in upstream activators of RAS such as growth factor receptors. Thus, RAS has emerged as an important therapeutic target in human carcinogenesis.
RAS proteins cycle between active GTP-bound and inactive GDP-bound states. These two states of RAS are controlled by guanine nucleotide exchange factors (GEFs) that promote the release of GDP from RAS and subsequent uptake of GTP. The nucleotide exchange process leads to large conformational changes of the switch-1 (SW1) and switch-2 (SW2) regions in the effector lobe of RAS. Once activated, RAS signaling is terminated through the action of its intrinsic GTPase activity that is enhanced by GTPase accelerating proteins (GAPs). Given the importance of RAS in driving cellular transformation and tumorigenesis, much effort has been devoted to developing pharmacological inhibitors to RAS. Although farnesyl transferase (FTase) inhibitors appeared a promising solution to inhibit RAS in vivo, these inhibitors have proven ineffective against mutant K-RAS due to the inherent ability of K-RAS to undergo alternative lipid modification upon blockade of the FTase. More recent efforts have led to the identification of distinct RAS inhibitory agents. Using a disulphidebased screening approach, irreversible inhibitors specific to the K-RAS(G12C) mutant were identified that shift the nucleotide preference of K-RAS(G12C) toward GDP and impair Raf activation 3 . In addition, synthetic α-helical peptides have been isolated that interfere with Sos-mediated nucleotide exchange on RAS and inhibit RAS function in cells 4, 5 .
We have taken a different approach to inhibit RAS through employing the monobody technology 6, 7 . Monobodies are high affinity, synthetic proteins constructed based on the molecular scaffold of the fibronectin type III domain that often target functionally important sites of their respective target and thus can act as inhibitors 8 .Unlike conventional antibodies, monobodies are insensitive to the redox potential of their environment and hence can be readily utilized as genetically encoded inhibitors 9 . High affinity monobodies have been isolated to a diverse array of targets including the extracellular domain of receptors, kinases, steroid hormone receptors, and modular protein domains 6, 8 . Here, we report the isolation of a high affinity monobody, termed NS1, that selectively binds both H-RAS and K-RAS. NS1 potently inhibits H-RAS and K-RAS mediated signaling and transformation. Finally, biochemical and structural analyses reveal that NS1 inhibits RAS through binding a previously unrecognized interface important for dimerization/nanoclustering of RAS proteins. These findings reveal a novel approach to inhibit RAS-mediated signaling and transformation that is critical for RAS activation of RAF.
RESULTS

NS1 monobody selectively binds H-RAS and K-RAS
Given the challenges in pharmacologically inhibiting activated RAS 10 , we hypothesized that there may exist functionally critical sites outside SW1 and SW2 that can be targeted for inhibition. To identify such sites, we generated monobodies specific for RAS. As a part of our ongoing investigation of H-RAS 11 , we performed combinatorial library selection for monobodies that interacted with H-RAS in an unbiased manner with respect to their binding sites. We identified a monobody, termed NS1, that bound H-RAS with low nM affinity and K-RAS with slightly weaker affinity (Fig. 1a) . Further, NS1 showed no detectable binding to N-RAS (Fig. 1a) .
A series of cell-based experiments further supported the specificity and potency of NS1. Cyan fluorescent protein (CFP)-NS1 co-localized with YFP-tagged H-RAS and K-RAS, both on the plasma membrane and intracellular vesicles 12 , but did not co-localize with YFP-N-RAS (Fig. 1b) . In bimolecular fluorescence complementation (BiFC) assays, NS1 interacted equally well with wild type, constitutively activated and dominant negative H-RAS (Supplementary Results, Supplementary Fig. 1 ), suggesting that NS1 does not exhibit preference for the activation state of RAS, consistent with the in vitro binding profile (Fig.   1a) . Finally, CFP-NS1, but not CFP alone, specifically captured H-RAS and to a lesser extent, K-RAS from cells, but did not capture N-RAS or the related RAS-like GTPase TC21/R-RAS2 (Fig. 1c) . Thus, NS1 is specific to the H-and K-Ras members of the oncoprotein branch of the RAS subfamily 13 .
NS1 monobody inhibits RAS-mediated signaling
When used as a genetically encoded, intracellular reagent, NS1 potently inhibited EGF activation of ERK-MAPK (Fig. 2a) . NS1 attenuated ERK-MAPK activation by oncogenic H-RAS and K-RAS but not by oncogenic N-RAS, as anticipated from its binding specificity described above. Furthermore, NS1 did not inhibit signaling mediated by oncogenic BRAF or MEK1 (Fig. 2b and Supplementary Fig. 4a ). The effect of NS1 on RAS-mediated signaling was not limited to ERK-MAPK activation; NS1 also inhibited AKT activation by oncogenic H-RAS and K-RAS but not by N-RAS ( Fig. 2c and Supplementary Figs. 4b and  4c ).
NS1 monobody inhibits RAS-mediated transformation
We next examined whether these effects of NS1 monobody on RAS-mediated signaling translated to comparable effects on RAS-mediated transformation. Consistent with the above molecular signaling analyses, NS1 inhibited transformation of cells by oncogenic HER2/ Neu, H-RAS, and K-RAS but not N-RAS, BRAF, or MEK ( Fig. 2d and Supplementary Fig.  5a ). These results demonstrate that NS1 selectively inhibits signaling and oncogenic transformation by H-RAS and K-RAS but does not block the closely related family member, N-RAS, or oncogenic kinases downstream of RAS, e.g., RAF and MEK.
Next, we examined the ability of NS1 to target oncogenic RAS in human tumor cells using an inducible expression system. Expression of NS1 as a CFP fusion protein, but not CFP alone, inhibited endogenous H-RAS(G12V)-mediated ERK activation and proliferation in bladder carcinoma cells ( Fig. 2e and Supplementary Fig. 5b ) but did not affect ERK activation or proliferation of melanoma cells harboring a mutant BRAF allele [BRAF(V600E)] (Fig. 2f) . Thus, NS1 specifically inhibits endogenous mutant H-RAS but not downstream oncogenic kinases in human tumor cells.
NS1 does not affect nucleotide exchange on H-RAS
Because inhibitors of RAS-mediated signaling have been discovered that interfere with Sosmediated nucleotide exchange 4, 5, 14 and prevent nucleotide loading 15 , we tested whether NS1 might affect Sos-mediated nucleotide exchange. As anticipated from the observation that NS1 binding is insensitive to the nucleotide state of RAS (Fig. 1a) , NS1 did not promote nucleotide release from H-RAS ( Supplementary Fig. 7a ) or block nucleotide exchange ( Supplementary Fig 7b) , thus excluding these modes of action for its inhibitory activity.
Structural basis of NS1-RAS interaction
To define the mechanism by which NS1 inhibits H-RAS mediated signaling, we determined a 1.4 Å-resolution crystal structure of NS1 in complex with GDP-loaded H-RAS (Supplementary Table 1 ). The structure revealed interaction of NS1 with the α4, β6, and α5 regions within the so-called allosteric lobe 16 , which lie on the surface of RAS in opposition to SW1 and SW2 (Fig. 3a) . This surface is also distinct from the RAS surface that binds a distal RAS-GTP activation site in Sos 17 . To our knowledge, no other RAS-interacting proteins have been reported to bind this surface. The interface is small for high-affinity protein interaction, with a buried surface area of 568 Å 2 , but tightly packed with a shape complementarity value of 0.862. The H-RAS molecule maintained its conformation as observed in published structures (Supplementary Fig. 8a ). NMR chemical shift perturbation data (Fig. 3b) support the observed binding interface in solution. Furthermore, the lack of significant perturbations of HSQC resonances of H-RAS in the so-called effector lobe upon binding of NS1 to the allosteric lobe suggests that NS1 does not promote inter-lobe communication 16 . The FG loop of NS1, one of the loops that are diversified in the monobody library, forms two short β-strands that dock onto β6 of H-RAS and extend the central β-sheet of H-RAS (Supplementary Fig. 8b ). In addition, NS1 utilizes predominantly aromatic side chains for interacting mainly with α4 of H-RAS ( Supplementary Fig. 8c ), as expected from our design of monobody combinatorial libraries 7 .
NS1 makes extensive contacts with Arg135 of H-RAS, a residue identical in K-RAS but not N-RAS (Lys) (Fig. 3c) . The Arg135 side chain forms a total of five polar interactions with surrounding residues (plus another with the water molecule) (Fig 3d) . Tyr31 and Trp75 form a cage-like structure that restricts the conformation of Arg135 side chain, and there is also pi stacking between Tyr31 and Arg135. Based on this crystal structure, substitution of Arg135 with Lys as present in N-RAS would disrupt most of these contacts. Indeed, mutation of R135 to K or A in H-RAS(G12V) dramatically reduced NS1 binding rendering H-RAS resistant to NS inhibition ( Fig. 3e and Supplementary Figs. 9a and 9b ). These results confirm that Arg135 is a major specificity determinant and explains why NS1 does not bind or inhibit N-RAS ( Figs. 1 and 2 ).
RAS crystal structures exhibit preferred dimer interface
To determine the relationship between NS1 binding and RAS inhibition, we systematically analyzed 113 available crystal structures of H-RAS (Fig. 4a) . We consistently observed a specific dimer form, termed the α4-α5 dimer, in structures of H-RAS in the active state (as defined by the SW1 and SW2 conformations 18 ) which was not present in inactive H-Ras structures ( Fig. 4a and Supplementary Tables 2 & 3 ). This mode of dimerization existed across ten distinct crystal forms, suggesting that attainment of the α4-α5 dimer reflects an intrinsic property of active RAS and not an artefact of crystal packing. The α4-α5 dimer interface buries ~800Å 2 of surface area on RAS, a region distinct from and larger than that utilized by RAS to engage its effectors (~600Å 2 ). This dimer interface is distinct from surfaces utilized by RAS to bind GAPs 19 and GEFs 17, 20 . The α4-α5 dimer state is compatible with RAS being anchored in the membrane and orients the effector binding region on both RAS protomers parallel to the plane of the membrane ( Supplementary Fig.  9c ), which would be necessary for productive RAS:effector interactions. Strikingly, NS1 binds at the center of this putative dimerization interface (Fig. 4b & c) , thus precluding formation of the α4-α5 dimer in the presence of NS1. The α4-α5 dimer configuration is also present in the K-RAS(G12D) structure (PDB ID: 4EPR) 21 and overlaps a potential dimer interface identified in N-RAS by molecular modeling 22 and implicated in nanoclustering of RAS isoforms 23 . These observations suggest that this dimer configuration is conserved among RAS family members.
NS1 disrupts RAS dimerization/nanoclustering
Based on these observations, we hypothesized that NS1 inhibits oncogenic RAS-mediated signaling through blocking dimerization/nanoclustering of RAS thereby preventing RAF activation (Fig. 5a ). To directly test this hypothesis, we performed an electron microscopy (EM)-spatial analysis on RAS 24, 25 (see Online Methods for detailed description). NS1 significantly reduced RAS nanoclustering which is quantified by the peak L(r)-r value, L max ( Fig. 5b, Supplementary Figs. 11a and 11b ). Further analysis of the point patterns revealed that NS1 decreased the dimer/monomer ratio ( Fig. 5c ), as well as the population of multimers ( Supplementary Figs. 11c and d) , suggesting that NS1 disrupts RAS dimerization and subsequent nanoclustering. Consistent with these results, BRET analysis revealed that NS1 disrupted K-RAS but not N-RAS dimerization ( Fig. 5d and Supplementary Fig. 11e ). Thus, these findings suggest that NS1 disrupts dimerization/nanoclustering of both H-and K-RAS.
Residues within the α4-α5 interface, namely R135, D154 and R161, have been implicated in dimer formation 22 . However, charge-reversal mutations of these residues in the background of oncogenic H-RAS(G12V) did not affect ERK activation (Supplementary Figs. 9a, b and 12). These results indicate that these mutations are not sufficient to disrupt RAS signaling and suggest that these residues are not critical for RAS dimerization/ nanoclustering.
The EM-spatial analysis also revealed that association of K-RAS, but not H-RAS, with the plasma membrane was reduced by NS1 expression (Fig. 5e ). This observation is expected from the inhibition of dimerization by NS1. Each H-RAS molecule is firmly anchored by two palmitoyl chains and a farnesyl chain, but each K-RAS molecule is more weakly anchored by only a single farnesyl chain and a polybasic domain. Consequently, dimerization and oligomerization of K-RAS leads to substantially greater membrane binding avidity. NS1 binding reversed this process, resulting in dissociation of K-RAS. By contrast, each H-RAS molecule is firmly anchored by two palmitoyl chains and a farnesyl chain, rendering its membrane localization insensitve to the disruption of dimerization by NS1.
NS1 inhibits RAS-induced RAF activation
Recruitment and dimerization of RAF is a well established consequence of RAS activation 26, 27 . To evaluate the ability of NS1 to alter effector binding and plasma membrane recruitment, we performed bivariate EM-co-clustering analyses 25, 28, 29 . NS1 significantly reduced co-localization of K-RAS(G12V), but not H-RAS(G12V), with CRAF at the plasma membrane ( Supplementary Figs. 14a-c) . Furthermore, NS1 reduced the number of goldlabeled RAF molecules on the plasma membrane in K-RAS(G12V), but not H-RAS(G12V) samples ( Supplementary Fig. 14d ). These results are consistent with earlier work showing that K-RAS is more efficient at recruiting and retaining CRAF on the plasma membrane than H-RAS 29, 30 . Similar results were obtained by co-immunoprecipitation of oncogenic Hor K-RAS with RAF ( Fig. 6a and Supplementary Fig. 16a ) or binding to the RAF RBD ( Supplementary Figs. 16b and c) . In addition, NS1 did not affect binding of GTP loaded H-RAS to GST-RAF RBD in vitro ( Supplementary Fig. 16d ). Further, BRET analysis revealed that NS1 disrupts CRAF interaction with K-RAS(G12V) but not N-RAS(G12V) (Supplementary Figs. 18 and 19) . Thus, NS1 prevents dimerization and subsequent nanoclustering of oncogenic H-RAS and K-RAS at the plasma membrane resulting in decreased engagement of RAF by K-RAS but not H-RAS. As would be predicted, NS1
inhibits oncogenic H-and K-RAS-induced CRAF:BRAF heterodimerization (Figs. 6b, c, and Supplementary Fig. 19 ) 26, 27 and subsequent RAF activation (Fig. 6d , Supplementary  Fig. 21 ).
DISCUSSION
Development of effective RAS inhibitors represents a holy grail in cancer biology 10 . Our discovery of a potent monobody inhibitor that binds a region distinct from inhibitors that directly impair effector interactions with the switch regions 3,31-33 represents a novel strategy to inhibit oncogenic RAS-mediated signaling and transformation. Our multi-disciplinary study has substantially increased the support for the importance of the α4-α5 interface for RAS dimerization/nanoclustering, signaling and oncogenic transformation.
Although inhibition of kinase dimerization is a common theme in blocking signaling by RTKs 34 and the RAF-MAPK pathway 26, 35 , the role of dimerization in RAS function remains a point of significant debate. Radiation inactivation studies suggest that both wild type and mutationally activated RAS function in an oligomeric state 36 . Chemical dimerization of RAS induces RAF activation 37 and recent super resolution microscopy studies support the premise that RAS proteins form dimers 38 to promote RAF dimerization 37, 39 and activation 26 . Finally, EM-spatial mapping studies indicate that RAS proteins function in small, transient nanoclusters consisting of ~6-7 RAS proteins 24 that lead to RAF recruitment and activation. While these data support the premise that RAS dimerizes in the cellular context, clear demonstration of RAS dimerization has been enigmatic. A missing piece of this puzzle has been a tool to directly modulate RAS dimerization. Our results now establish that binding of NS1 to the α4-α5 interface of RAS reduces RAS dimerization/nanoclustering and prevents effector activation, suggesting that RAS dimerization is a requisite step in signal transmission.
In contrast to the characterization of full-length RAS in the cellular context, there are conflicting reports of whether the G domain of RAS forms dimers in solution 40, 41 . This dimerization interaction is certainly weak, as the G domain is predominantly monomeric in solution even at high protein concentrations. However, RAS dimers are observed at extremely high protein concentrations such as in crystal structures (Fig. 4A and  Supplementary Tables 2 & 3) 22 . These seemingly conflicting observations can be reconciled by the fact that tethering of RAS to the plasma membrane through its C-terminal lipid modifications reduces the dimensionality and thus increases the effective local concentration of RAS, increasing the probability of dimer formation 38 . The detection of RAS dimers in the cellular context may also be facilitated by RAF that has an intrinsic property to dimerize 26 . Nevertheless, our results with NS1 monobody clearly demonstrate the importance of the α4-α5 interface for RAS-induced dimerization of RAF.
The α4-α5 interface has been proposed as a dimerization interface in RAS proteins, with specific residues contributing to the formation of the proposed dimer 22 . However, mutation of several of these residues (namely R135, D154 and R161) 22 did not affect oncogenic H-RAS-mediated activation of ERK ( Supplementary Figs. 9a, b and 12) . This difference between perturbation by point mutations and by the NS1 monobody is intriguing and indeed provides mechanistic insights into the nature of RAS dimerization/nanoclustering. Our results suggest that individual RAS protomers may not need to physically interact through a single, specific mode of protein-protein interaction. Rather, upon GTP binding, the α4-α5 regions of RAS may reorient in close proximity to promote RAF dimerization and activation. Binding of NS1 to the α4-α5 interface would provide significant steric interference to this clustering thereby preventing RAS-induced effector dimerization, whereas a mutation may not. Alternatively, NS1 binding may alter the orientation of RAS with the plasma membrane thereby inducing an autoinhibited conformation 42 . Further studies combining multiple biophysical techniques will define the atomic details of RAS dimer/nanocluster.
Our results with NS1 monobody also highlight differences between H-RAS and K-RAS in terms of their localization at the plasma membrane and their engagement of RAF. Although NS1 has a roughly 5-fold higher affinity for H-RAS vs K-RAS, engagement of NS1 reduced the amount of K-RAS at the plasma membrane and the recruitment of RAF while the amount of H-RAS at the plasma membrane and the H-RAS:RAF interaction remained relatively refractory to NS1 binding. Several possibilities may explain these differences. The displacement of K-RAS from the plasma membrane upon binding NS1 may result in decreased engagement of RAF. Furthermore, NS1 may promote differing degrees of membrane occlusion of the effector binding region in K-RAS vs H-RAS due to differences in their orientational equilibrium 42 . Such an effect may be different for H-RAS and K-RAS because their distinct C-terminal modifications may result in differences in the dynamic interaction with the membrane. In addition, RAS proteins exhibit intramolecular communication between the allosteric and effector lobes 16 . While our structural analyses suggest that NS1 does not promote significant inter-lobe communication in H-RAS, K-RAS could exhibit more significant conformational perturbations upon NS1 binding resulting in allosteric changes in the effector domain. Nevertheless, it is clear that for both H-RAS and K-RAS, NS1 engagement of the α4-α5 interface inhibited RAS-induced RAF dimerization and activation. Future studies will determine the precise molecular explanation for these differences and the possibility of exploiting them for selective targeting of RAS isoforms. Andrew Aplin) were grown in DMEM with 10% FBS. All growth media were commercially purchased (Corning). HEK-293, HEK-293T, COS1 and NIH-3T3 cells were transiently transfected using empirically determined concentrations of polyethyleneimine (PEI) along with Opti-Mem reduced serum media (Life Technologies) and serum-free DMEM. NS1 was PCR amplified from the monobody vector using primers: 5'CTCGAGACTACAAAGACGATGACGACAAGGGATCCGTTTCTTCTGTTCCGACCA A3' and 5'CTCGAGTCAGGTACGGTAGTTAATCGA3', digested with XhoI and cloned into the XhoI site of the cyan fluorescent protein tagged, pECFP-C1 and the BiFC vector VC-155 for mammalian cell expression. pTRIPz-CFP (control) and pTRIPz-CFP-NS1 vectors were generated by modification of the original pTRIPz vector (Thermo Scientific Open Biosystems). pTRIPz was digested with AgeI and MluI to remove both tRFP and the shRNAmir sequences. PCR amplified CFP or CFP-NS1 fragments from the pECF-C1 vector were cloned into pTRIPz using In-Fusion Cloning (Clontech) following manufacturers instructions.
Online Methods
Antibodies
The following antibodies were purchased from commercial sources: ERK1/ 
Generation of stable lines
HEK-293T cells were used to generate lentivirus for infection of T24 cells. These packaging cells were PEI transfected using 20 µg of either pTRIPz-CFP or pTRIPz-CFP-NS1 along with a plasmid encoding the pMD2.G the viral envelope and pCMVdR8.74 to generate viral particles. The following day packaging cells were placed in fresh media and cells were seeded for infection. On day 2 post-transfection, conditioned media from the HEK-293T cells were collected, filtered, and used to infect cells followed by selection in 750 ng/ml puromycin. Following selection colonies were pooled to generate a polyclonal cell line, which was used for all subsequent analyses.
Protein expression and purification
Bacterially expressed GST fusion proteins and H-RAS have been previously described 11 . H-RAS (Uniprot: P01116, residues 1-166, and residues 1-174), K-RAS (Uniprot:P01116, isoform 2B, residues 1-174), N-RAS (Uniprot: P01111, residues 1-174) and NS1 monobody were prepared as a fusion C-terminal to His 6 , a biotin-acceptor tag, and a TEV cleavage site using an in-house vector termed pHBT 9 . Mutations were introduced using the method of Kunkel et al. 43 . The proteins were produced in E. coli BL21(DE3) containing the pBirAcm plasmid (Avidity) in the presence of 50 µM D-biotin for in vivo biotinylation.
They were purified using Ni-Sepharose columns (GE-Healthcare). Their purity and monomeric state were confirmed using a Superdex 75 size-exclusion column (GE Healthcare) and mass spectroscopy. For crystallization, the proteins were expressed in BL21(DE3) without the addition of biotin in the media, purified as described above and the affinity tags for each protein were removed using the tobacco etch virus (TEV) protease. The cleaved tag and uncleaved protein were removed by passing the sample through a NiSepharose column.
Monobody generation and characterization
Given our prior interests in understanding the function of different nucleotide bound states of H-RAS 11 , we initially sought to isolate high affinity reagents to different nucleotide states of this GTPase. For monobody selection, biotinylated H-RAS (residues 1-166) was used. For testing isoform specificity, biotinylated RAS samples containing residues 1-174 were used, because the G-domain of K-RAS extends beyond residue 166. The biotinylated H-RAS protein bound to GDP or GTPγS was prepared by incubating the H-RAS sample prepared from E. coli with 1 mM GDP or GTPγS in 20 mM Tris-HCl buffer pH 7.5 containing 15 mM EDTA, 5 mM MgCl 2 and 1 mM DTT for 30 min at 30°C followed by an addition of MgCl 2 at a final concentration of 20 mM and incubation on ice for 5 min. The apo H-RAS protein was prepared by the same way except that no nucleotide was added.
General methods for phage-and yeast-display library sorting and gene shuffling have been described 7, 8 . The NS1 monobody was isolated from the "side-and-loop" combinatorial library constructed in the phage display format 7 as follows. We performed three separate selections using H-RAS apo, H-RAS/GDP and H-RAS/GTPγS in parallel. Four rounds of phage-display selection were performed in the TBS/Mg/BSA/TCEP buffer (50 mM TrisCl, 150 mM NaCl, pH7.5, 20 mM MgCl 2 , 5 mg/ml BSA, 0.2 mM TCEP), using protein concentrations of 100, 100, 50 and 50 nM for the first through fourth rounds. In each round, phage clones that bound to the target were captured using streptavidin-coated magnetic beads and amplified. The monobody genes from the enriched clones were amplified using PCR and the segments encoding to the N-and C-terminal halves of the monobodies were recombined and assembled, as detailed previously 7 . This "gene-shuffled" pool of monobody genes were used to transform yeast EBY100 to construct a library in the yeast display format. Two rounds of yeast-display library sorting were performed using 100 and 50 nM protein concentrations, as described using a FACS Aria sorter (BD Biosciences). Individual clones were grown and tested for binding to H-RAS/GTPγS and H-RAS/GDP. The NS1 monobody was recovered from all three selection campaigns.
Quantitative binding measurements in the yeast display format were performed using a Millipore Guava flow cytometer as described previously 7, 8 . Individual clones from sorted libraries were isolated on agar plates and grown in liquid media. Approximately 100,000 yeast cells for each clone were incubated with various concentrations of biotinylated target in BSS/Mg/TCEP buffer for H-RAS/GDP and H-RAS/GTPγS, and in BTE/TCEP buffer [20mM TrisCl (pH7.5), 15mM EDTA, 1mg/ml BSA, 0.2mM DTT] for H-RAS apo at room temperature for 30 min with shaking. The yeast cells were washed and stained with neutravidin-Dylight 650 conjugate (Thermo Fisher Scientific) in the wells of a 96-well filter plate (MultiScreenHTS HV, 0.45 µm pore size; Millipore). The stained cells were analyzed using a Guava EasyCyte 6/L flow cytometer (Millipore). The K D values were determined from plots of the mean fluorescence intensity versus target concentration by fitting the 1:1 binding model using the KaleidaGraph program (Synergy Software). We have validated using numerous monobodies that K D values measured in this manner are consistent with those determined from biophysical methods using purified monobodies 7, 9, 44 .
Crystallization, diffraction data collection and structure determination
The NS1 and H-RASGDP proteins were mixed in a 1:1 molar ratio, and the complex was purified using a Superdex 75 column. The complex was concentrated to a total protein concentration of 16 mg/mL in 10mM Tris-Cl buffer pH 8.0 containing 50 mM NaCl, 20 mM MgCl 2 and 0.5 mM TCEP. Crystals were obtained in 0.2M ammonium fluoride, 20% PEG 3350, pH 6.2, at 19 °C by the hanging-drop vapor diffusion method. Crystals were frozen in a mixture of 75% mother liquor and 25% ethylene glycol. X-ray diffraction data were collected at the X-ray Operations and Research beamline 19-BM-D at the Advanced Photon Source, Argonne National Laboratory at a wavelength of 0.979 Å and at 100 K. Data collection information is reported in Supplementary Table 1. Diffraction data were processed and scaled with the HKL-3000 package 45 . The NS1/H-RAS166 structure was determined by molecular replacement in Phaser 46 . A multicopy search was performed using an H-RASGDP Structure (PDB ID: 4Q21) and a monobody structure excluding the loop regions (PDB ID: 4JE4). Manual model building, solvent addition, and refinement of the structure was conducted iteratively using Coot 47 and phenix.refine 48 . Model validation was conducted using the Molprobity server 49 as well as the Protein Data Bank validation server. The final structural model was of good geometry, with 98.4% of residues in favored regions and 1.6% in allowed regions of the Ramachandran analysis. Molecular graphics were generated using PyMOL 50 . Surface area calculations were performed using the PROTORP protein-protein interaction server 51 . Shape complementarity was determined using the Sc statistic 52 .
Cell signaling assays
ERK and AKT activation assays were measured by transfecting HEK293 cells with MYC-ERK or HA-AKT constructs along with the indicated expression constructs. Following immunopurification of the tagged kinase, samples were analyzed for activation of ERK/AKT by Western blot with phosphospecific antibodies. Activation was quantified by densitometry using ImageJ. Quantification of kinase activation was determined by dividing the level of phosphokinase by that of total kinase and normalizing to unstimulated, vector control sample. Experiments were performed in triplicate. RAS activation was determined essentially as previously described 53 . HEK 293 cells were transiently transfected with the indicated constructs, serum starved overnight in DMEM alone and stimulated with EGF (100 ng/ml for 10 min) where indicated. Oncogene transfected cells were not stimulated with growth factor. Cells were then lysed in GTPase buffer containing (25 mM HEPES, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 25 mM MgCl 2 , 1 mM EDTA, 25 mM NaF, 0.25% DOC, pH 7.5) and incubated at 4 °C for 1 hour with either GST or GST-RAF RBD. Precipitated HA-H-RAS was examined by Western blot and quantified by densitometry using ImageJ. Relative RAS activity was determined by dividing precipitated HA-H-RAS by the total HA-H-RAS in whole cell lysates. Interaction of RAS-family GTPases with NS1 in cells was measured by co-immunoprecipitation. Briefly, HEK-293 cells were transfected with the indicated constructs. Following immunoprecipitation of CFP or CFP-NS1, samples were analyzed by Western blot using the indicated antibodies for co-precipItation of the indicated HA-tagged GTPases. RAS interaction with RAF was also measured by coimmunoprecipitation. Briefly, T24 cells stably transfected with pTRIPz constructs encoding with CFP or CFP-NS1 were induced to express for 48 hours with 2 µg/ml doxycycline. Following immunoprecipitation of endogenous RAS, samples were analyzed by Western blot for co-precipitation of CRAF, BRAF, and monobody. Experiments were performed in triplicate. RAF activation was measured essentially as described 54 . Briefly, HEK-293 cells were transfected with the indicated constructs. Following immunopurification of endogenous CRAF, samples were incubated with purified kinase-dead MEK1 in an in vitro kinase reaction containing: 20 mM Tris (pH 7.4), 20 mM NaCl, 1 mM DTT, 10 mM MgCl 2 , 1 mM MnCl 2 and 20 µM ATP for 30 minutes at 30°C with constant shaking. Reactions were terminated by addition of boiling hot sample buffer and then analyzed by Western blot using a phosphospecific MEK antibody (Cell Signaling).
Bimolecular fluorescence complementation
Expression constructs consisting of the FLAG-tagged N-terminus or HA-tagged C-terminus of Venus (VN and VC, respectively) were kindly provided by Chang-Deng Hu. All H-RAS and NS1 cDNA sequences were cloned into these vectors such that the Venus fragments were fused to the N-terminus of the respective protein. COS1 cells were transiently transfected late in the day and then imaged the following morning. CFP was co-transfected along with the BiFC constructs, but at a five fold-lower amount, to mark transfected cells.
Cell viability assays
T24 or A375 cells (1000 per well) were plated on 24-well plates in complete media (McCoy's 5A with 10% FBS plus 0.75 µg/ml puromycin and 2 µg/ml doxycycline to induce expression from the pTRIPz constructs) for the indicated number of days. On the indicated day, media was removed and replaced with 100 µl of serum-free McCoy's 5A, cells were harvested after 30 minutes at 37°C. Viability was assayed using CellTiter Glow (Promega). Luminescence was quantified on a Dynex 96-well microtiter plate luminometer according to the manufacture's instructions.
Transformation assays
NIH 3T3 cells were seeded in 60 mm dishes to a density of 2.5 × 10 5 cells in complete media. Cells were transfected with indicated constructs. Media changes were performed every 3 days. Foci were counted and stained after 14 -21 days. All assays were performed in triplicate and repeated three times with the exception of NeuT which was only performed twice.
Identification of H-RAS α4-α5 dimeric assemblies in the Protein Data Bank
The α4-α5 H-RAS dimeric structure (Protein Data Bank, PDB ID 5p21 55 ) was used as a template. The PISA server 56 was utilized to search the entire PDB for all H-RAS structures in which i) the α4-α5 dimer conformation was found, and ii) in which the α4-α5 dimer was not found. The 39 structures in which the specific dimer was not found were further analyzed in PyMol 50 to manually compare the tertiary structure to determine its active state based on the conformation of switch regions 18 as superimposed on the active state PDB ID 5P21.
BRET assays
HEK293T cells were maintained in DMEM supplemented with 10% FBS and Penicillin/ Streptomycin. For titration curves, 1.5 × 10 5 HEK293T cells were seeded in 12-well plates and transfected the next day with polyethylenimine (PEI) 57 . Forty-eight hours posttransfection, cells were washed, resuspended in HBSS buffer (Wisent) and transferred to white opaque 96-well microtiter plates (Greiner). BRET measurements were done as follows. BRET signals and luciferase activity were read 15 minutes post-addition of 2.5 µM Coelenterazine 400a (Biotium) using a Victor plate reader (Perkin Elmer) equipped with BRET2 emission filter set (donor: 400nm ± 20 nm; acceptor: 510 nm ± 20 nm). BRET signals correspond to the light emitted by the GFP10 acceptor constructs (510 nm ± 20 nm) upon addition of Coelenterazine 400a divided by the light emitted by the RlucII donor constructs (400 nm ± 20 nm). Total GFP10 or mCherry levels were separately detected on a FlexStation II (Molecular Devices) with excitation and emission peaks set at 400 and 510 nm, and 580 and 635 nm, respectively. Total intrinsic GFP10 (expressed as Relative Fluorescence Units; RFU) and RlucII (Relative Luminescence Units; RLU) signals were used as proxies to ensure that similar protein expression was obtained across conditions ( Supplementary Figs. 18 and 19 ). For more detailed BRET procedures, see Lavoie et al. 2013 Supplementary Note 1 57 .
Nucleotide exchange assays
Nucleotide release was measured essentially as described 17 . H-RAS was purified from bacteria and buffer exchanged with PD-10 columns (GE Healthcare) into nucleotide loading buffer (20 mM Tris-HCl, 50 mM NaCl, 4 mM EDTA, 1 mM DTT, pH 7.5) and loaded with MANT-GTP (Life Technologies). Unincorporated MANT-GTP was removed and MANT-GTP-loaded H-RAS was exchanged into reaction buffer (40 mM HEPES-KOH, 10 mM MgCl 2 , 1 mM DTT, pH 7.5) using NAP-5 columns (GE Healthcare). Reactions were initialized by addition of the indicated proteins. Nucleotide incorporation was measured essentially as described 58 . H-RAS was exchanged into reaction buffer (20 mM TRIS-HCl, 50 mM NaCl, 10 mM MgCl2, 1 mM DTT, pH 7.5) using NAP-5 columns. H-RAS was preincubated with NS1 for 10 minutes where indicated. Reactions were initialized by addition of 400 nM MANT-GTP and SOScat (where indicated). All nucleotide exchange assays were performed at room temperature for 1800 seconds. Fluorescence was excited at 355 nm, and emission was monitored at 460 nm using a FlexStation ™ II (Molecular Devices Corporation) 96-well plate reader.
Monobody competition for RAS-RAF interaction
Bacterial expressed H-RAS was incubated in Loading Buffer (20 mM Tris-HCl, pH 7.6, 15 mM EDTA, 5 mM MgCl 2 , 1 mM DTT, 0.1 mM PMSF, 10% glycerol) with either 1mM GTPγS or 1mM GDP for 30 minutes at 30°C. The reaction was quenched with 65mM MgCl 2 and kept on ice for 10 minutes. After nucleotide loading, 250 nM HRAS was incubated with 125 nM, 250 nM, or 1.25 uM of NS1 for 15 mins at 4°C followed by addition of 850nM of GST-RAF RBD or GST. Reactions were incubated for 1 hr at 4°C. Beads were then washed 3× with Washing Buffer (10 mM Tris-HCl, pH 7.6, 5 mM MgCl 2 , 10% glycerol, 1 mM DTT, 0.1% TritonX-100, 0.1 mM PMSF) and run on an SDS-PAGE gel to visualize bound proteins by Coomassie staining.
EM-Spatial Mapping
To directly test the effect of NS1 on RAS dimerization/nanoclustering, we co-expressed GFP-tagged K-RAS(G12V) with RFP empty vector or RFP-NS1 in baby hamster kidney (BHK) cells and performed an EM-spatial analysis which has been described in detail elsewhere 24, 59, 60 . Briefly, the apical plasma membrane of BHK cells transiently expressing GFP-tagged RAS proteins, along with RFP empty vector or RFP-NS1, was attached to copper EM grids. After fixation with 4% paraformaldehyde (PFA) and 0.1% glutaraldehyde, GFP-RAS on the plasma membrane was immuno-labeled with 4.5nm gold nanoparticles pre-coupled to anti-GFP antibody, which was then embedded in uranyl acetate. Gold particle distribution was visualized by transmission EM (TEM) imaging using JEOL JEM-1400 transmission EM. ImageJ was then used to assign×and y coordinates of gold particles in a 1-µm 2 area on intact and featureless plasma membrane sheets. Ripley's K-function was used to calculate the gold particle distribution and the extent of nanoclustering 24, 59 :
where K(r) is the univariate K-function for a distribution of n points in a selected plasma membrane area A and indicates the extent of nanoclustering; r = length scale with a range of 1 < r < 240 nm at 1-nm increments; ‖ ˙ ‖ is Euclidean distance; indicator function of 1(˙) has a value of 1 if ‖x i −x j ‖ ″ r and a value of 0 otherwise; and describes the circumferential fraction of the circle with center x i and radius ‖x i −x j ‖ within area A. An unbiased edge correction was included for points at the edge of the study area. Monte Carlo simulations then estimated a 99% confidence interval (99% C.I.), which was used to normalize K(r) to yield L(r) − r. The extent of nanoclustering is quantified by the peak L(r)−r value, L max . The model tests the null hypothesis that a completely random distribution of gold particles yields a L(r) − r value of 0 for all values of r. At least 15 PM sheets were imaged, analyzed and pooled for each condition. Statistical significance between different conditions was evaluated against 1000 bootstrap samples, which were constructed exactly as described 29 .
EM-Spatial Mapping-Bivariate K-function analysis
The bivariate K-function analyzes co-clustering/co-localization between RAS and CRAF on the plasma membrane inner leaflet. BHK cells were co-transfected with GFP-RAS and RFP-CRAF, along with GST empty vector or GST-NS1. Apical plasma membrane was attached and fixed to copper EM grids, which were then immuno-labeled with both 2nm gold coupled to anti-RFP antibody and 6nm gold coupled to anti-GFP antibody. Followed by EM imaging, x and y coordinates of both population of gold particles were assigned using ImageJ. Co-distribution between 6nm and 2nm gold populations was analyzed using a bivariate K-function. (Eqs. C-F):
where the bivariate estimator, K biv (r), consists of two individual bivariate K-functions: K bs (r) estimates the spatial distribution of 6nm (big, assigned as "b") gold particles with respect to each 2nm (small, assigned as "s") gold particle whereas K sb (r) quantifies the distribution of the small gold particles around each big gold particle. A selected plasma membrane sheet area A contains n b , number of 6-nm gold particles and n s , number of 2-nm small gold particles. Other symbols are the same as described in Eqs.A and B. Monte Carlo simulations then estimated the 95% confidence interval (95% C.I.), which was used to normalize K biv (r) to yield L biv (r)-r which evaluates the co-clustering at the length scale r.
Here, we aim to test the null hypothesis that complete spatial segregation between big and small gold populations yields a L biv (r)-r value of 0 for all values of r. Positive deviation above the 95% C.I. indicates statistically meaningful co-localization between GFP-RAS and RFP-CRAF. We then calculated the area-under-the-curve for each L biv (r)-r curve over a fixed range 10 < r < 110 nm to yield the bivariate L biv (r)-r integrated (or LBI) to quantify the extent of co-localization or co-clustering between RAS and CRAF: (Eq. G) At least 15 PM sheets were imaged, analyzed and pooled for each condition. Data are presented as mean ± s.e.m. Bivariate statistical significance between conditions was evaluated via comparing against 1000 bootstrap samples, which was constructed exactly as described 60 .
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. . Seventy-four of 80 active state H-RAS structures contained α4-α5 dimers but no α4-α5 dimers were present in inactive state structures. A protomer (shown in gray) of the α4-α5 dimers from six active state H-RAS structures (PDB ID, 5P21, 1AGP, 4L9W, 2C5I, 3K9L, and 3KUD) were superimposed using Pymol. SW1 and SW2 regions are highlighted yellow. b, NS1 monobody binds the α4-α5 dimer interface as highlighted in brown. The dimer interface shown is from PDB ID: 5P21. These regions overlap with the presumed dimerization interface identified in N-RAS 22 . c. Comparison of NS1 binding surface (highlighted red) and α4-α5 dimer interface (denoted with black boarder) on H-RAS structure. Supplementary Fig. 19. d, Effect of 
